Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
0.652 USD | +12.41% | -3.05% | +14.39% |
May. 30 | Day One Biopharmaceuticals Sells Priority Review Voucher for $108 Million | MT |
May. 23 | Oppenheimer Adjusts Price Target on Viracta Therapeutics to $11 From $13, Maintains Outperform Rating | MT |
Financials (USD)
Sales 2024 * | - | Sales 2025 * | 2.33M | Capitalization | 22.78M |
---|---|---|---|---|---|
Net income 2024 * | -62M | Net income 2025 * | -83M | EV / Sales 2024 * | - |
Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | 9.76 x |
P/E ratio 2024 * |
-0.5
x | P/E ratio 2025 * |
-0.54
x | Employees | 40 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 97.2% |
Latest transcript on Viracta Therapeutics, Inc.
1 day | -19.19% | ||
1 week | -21.72% | ||
Current month | -17.11% | ||
1 month | -28.39% | ||
3 months | -38.28% | ||
6 months | +24.56% | ||
Current year | +1.79% |
Managers | Title | Age | Since |
---|---|---|---|
Mark Rothera
CEO | Chief Executive Officer | 61 | 22-09-18 |
Chief Tech/Sci/R&D Officer | - | - | |
Darrel Cohen
CTO | Chief Tech/Sci/R&D Officer | 59 | 23-08-06 |
Members of the board | Title | Age | Since |
---|---|---|---|
Ivor Royston
BRD | Director/Board Member | 79 | 07-09-30 |
Thomas Darcy
BRD | Director/Board Member | 74 | 21-01-31 |
Barry Simon
BRD | Director/Board Member | 59 | 21-03-02 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.01% | 0 M€ | 0.00% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-06-05 | 0.652 | +12.41% | 91 349 |
24-06-04 | 0.58 | -19.22% | 322,454 |
24-06-03 | 0.718 | +2.57% | 54,372 |
24-05-31 | 0.7 | +1.43% | 47,782 |
24-05-30 | 0.6901 | +2.62% | 67,238 |
Delayed Quote Nasdaq, June 04, 2024 at 03:59 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+1.79% | 22.78M | |
+46.19% | 55.7B | |
+40.34% | 39.91B | |
-6.14% | 39.57B | |
-6.65% | 28.16B | |
+12.33% | 26.3B | |
-21.78% | 18.94B | |
+28.38% | 12.17B | |
+24.18% | 12.12B | |
-0.35% | 12.12B |
- Stock Market
- Equities
- VIRX Stock